Now we have a support at 0,25...lets go up...
This payment it will be very important...
Today we have a lot volume and i saw a lot of selling going on also.
That important to clear all the persons who bought around 0,15-0,20.
Now new buyers are coming at 0,25 0,26, and they will drive this stock up.
Price targets will now start to climb. It is real what is going on.
And they also receive a % of sales.
They will encrease the market value and they are not issuing a lot of shares, they now have around 358Million.
If this go around 0,5€ the value of Pharming will 179Million euros what isn´t to much!
A good future. Step by Step...And some corrections on the way.
This payment it will be very important...
Today we have a lot volume and i saw a lot of selling going on also.
That important to clear all the persons who bought around 0,15-0,20.
Now new buyers are coming at 0,25 0,26, and they will drive this stock up.
Price targets will now start to climb. It is real what is going on.
And they also receive a % of sales.
They will encrease the market value and they are not issuing a lot of shares, they now have around 358Million.
If this go around 0,5€ the value of Pharming will 179Million euros what isn´t to much!
A good future. Step by Step...And some corrections on the way.
Recent PHARM News
- Pharming Group receives positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older • GlobeNewswire Inc. • 03/27/2026 06:00:00 AM
- Pharming Group announces approval of Joenja® (leniolisib) in Japan for the treatment of APDS in patients aged 4 years and older • GlobeNewswire Inc. • 03/24/2026 06:00:00 AM
- Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow • GlobeNewswire Inc. • 03/12/2026 06:00:00 AM
- Pharming Group announces 2026 financial guidance and highlights rare disease pipeline at Investor Day • GlobeNewswire Inc. • 02/03/2026 06:00:00 AM
- Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja® (leniolisib) in children aged 4 to 11 years with APDS • GlobeNewswire Inc. • 02/01/2026 08:17:00 PM
- DAX, CAC, FTSE100, European equities drift lower amid U.S.–Venezuela tensions and data watch • UK Market News • 01/08/2026 02:17:15 PM
- Pharming Group reports preliminary 2025 revenues and announces Investor Day • GlobeNewswire Inc. • 01/08/2026 06:00:00 AM
- Pharming Group reports third quarter 2025 financial results with significant growth in revenue, profitability and cash flow • GlobeNewswire Inc. • 11/06/2025 06:00:00 AM
- Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio • GlobeNewswire Inc. • 10/20/2025 06:00:33 AM
- Pharming Group provides update on previously announced G&A expense reduction plan • GlobeNewswire Inc. • 10/06/2025 03:35:57 PM
- Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years • GlobeNewswire Inc. • 10/01/2025 05:00:25 AM
- Pharming Group promoted to the Euronext AMX® index • GlobeNewswire Inc. • 09/10/2025 05:00:00 AM
- Pharming Group appoints Kenneth Lynard as Chief Financial Officer • GlobeNewswire Inc. • 09/02/2025 05:00:00 AM
- Pharming Group reports second quarter and first half 2025 financial results and provides business update • GlobeNewswire Inc. • 07/31/2025 05:00:00 AM
- Pharming Group to host webcast on findings of a new study published in Cell advancing functional classification of variants of uncertain significance (VUS) to improve APDS diagnosis • GlobeNewswire Inc. • 06/24/2025 05:00:00 AM
- Pharming Group reports first quarter 2025 financial results and provides business update • GlobeNewswire Inc. • 05/08/2025 05:00:00 AM
- Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS) • GlobeNewswire Inc. • 04/25/2025 01:00:00 PM
- Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS • GlobeNewswire Inc. • 04/23/2025 07:30:00 AM
